

20 March 2023

ASX and MEDIA

RELEASE

Appointment of Chief Executive Officer

Dotz Nano Limited (ASX:DTZ) ("**Dotz**" or the "**Company**") announces that Mr Sharon Malka has been appointed Chief Executive Officer of the Company, effective immediately.

Mr Malka's appointment follows an extensive international recruitment process led by Dotz's Board of Directors. With the appointment of Mr Malka, Dotz Executive Chairman Mr Bernie Brookes AM will resume the role of Independent Non-Executive Chairman.

Mr Malka is an accomplished senior executive with over 20 years of strategic, operational, commercial and financial leadership in innovative technology companies. His international experience working for a range of organisations includes US listed companies and a track record in raising capital, mergers and acquisitions, building and managing high performance teams, developing technical assets and driving corporate growth.

Prior to joining Dotz, Mr Malka served as Chief Executive Officer of MediWound Ltd, a Nasdaq-listed biopharmaceutical company. During his time at MediWound, he directed the development of an innovative drug through world-wide regulatory approvals and led its global commercialization strategy via multiple distribution channels and collaborations, becoming the new standard-of-care. In addition, he established a certified pharmaceutical manufacturing capacity to support a global commercial launch. In doing so acquired an intimate understanding of technology development roadmaps and commercialisation pathways.

Prior to that, Mr Malka was a partner at Variance Economic Consulting Ltd., a multi-disciplinary consulting boutique, specialising in financial services for international and local Hi-Tech clients. Mr Malka also served as a Senior Manager at PricewaterhouseCoopers Corporate Finance, where he gained extensive experience in company valuations, joint ventures and financial instruments for investments, M&A, and IPOs.

Mr. Malka is a certified CPA and holds a B.Sc. in Business Administration from the Business Management College in Israel and an M.B.A. from Bar Ilan University, Israel.

Commenting on the appointment, Mr Brookes said, "We are delighted to attract someone of Sharon's calibre as Chief Executive Officer of Dotz. His credentials, experience and track record are ideally suited to leading Dotz through its next phase of growth. Sharon's appointment underscores international confidence in the Dotz technology and his extensive senior management and commercialisation experience will play an important role in shaping and leading the Dotz strategy moving forward. Dotz's exciting future is in capable hands and we look forward to the fresh ideas and enthusiasm Sharon will bring to the role."

Mr Brookes added that the appointment of Mr Malka follows several key senior management and Board appointments.

"Dotz has undergone a significant acceleration of our strategy during the past 12 months and we now have in place a senior management and Board structure that will drive our strategy and seek new opportunities," Mr Brookes added.



Mr Malka said: “I am honoured to have the opportunity to lead Dotz and very excited about the opportunities that exist for the Company. I look forward to working closely with the Board and the rest of the talented Dotz team to leverage the Company’s technology platform. My passion is to advance the Dotz go-to-market strategies, deliver a step up in business performance and accelerate commercialisation for a number of growth initiatives as we work to deliver significant value for our clients, employees and shareholders.”

Material terms of Mr Malka’s contract and biography are outlined in the attached appendices.

-ENDS-

This announcement has been authorised for release by the Board of Dotz Nano Limited.

For further information, please contact:

Sharon Williams

Dotz Communications
+61 (0)414 520 529
info@dotz.tech

John Hurst

Dotz Communications
+61 (0)418 798 663
info@dotz.tech

About Dotz Nano Limited

Dotz Nano Limited (ASX:DTZ) is a technology leader in research, production and marketing of anti-counterfeiting, authentication and tracing solutions. Its unique products ValiDotz, Bio Dotz, Fluorensic and InSpec are exceptional solutions for numerous applications, such as: bio-imaging, liquids tagging, lubricants and DEF authentication, polymers tagging, anti-counterfeiting, brand & reputation protection and oil & gas industry.

To learn more about Dotz, please visit the website and corporate video via the following link www.dotz.tech



APPENDIX

Mr Sharon Malka – Key Terms of Appointment

Commencement date:	20 March 2023
Term:	Appointment on an on-going basis subject to termination by either party (see termination and notice below)
Fixed Remuneration:	New Israeli Shekels (NIS) 77,000 per month (A\$31,890** per month) with minimum remuneration increases based on Israel Consumer Price Index ("CPI"). ** Based on an exchange rate of NIS: A\$ of 0.41
Short-Term Incentives:	Short-Term Incentives of up to 30% of base salary, subject to achieving key performance indicators (KPI) defined by the Board
Long-Term Incentives*:	<ol style="list-style-type: none"> 2,000,000 (Tranche 1) with an exercise price that is 30% over the 30 day (means a Trading Day on which the Company's Shares have actually traded on ASX). volume weighted average market price as defined in Chapter 19 of the Listing Rules ("VWAP") as at the Commencement Date. These options vest* in 12 months from Commencement Date, are escrowed for a further 12 month period and expire 60 months from the Commencement Date; 2,000,000 (Tranche 2) with an exercise price that is 60% over the 30 day VWAP as at the Commencement Date. These options vest* in 24 months from Commencement Date, are escrowed for a further 12 month period and expire 60 months from the Commencement Date; 2,000,000 (Tranche 3) with an exercise price that is 90% over the 30 day VWAP as at the Commencement Date. These options vest* in 36 months from Commencement Date, are escrowed for a further 12 month period and expire 60 months from the Commencement Date; 2,000,000 (Tranche 4) with an exercise price that is 120% over the 30 day VWAP as at the Commencement Date. These options vest* in 48 months from Commencement Date, are escrowed for a further 12 month period and expire 60 months from the Commencement Date; and 1,375,000 (Tranche 5) with an exercise price that is 150% over the 30 day VWAP as at the Commencement Date. These options vest* in 60 months from Commencement Date, are escrowed for a further 12 month period and expire 72 months from the Commencement Date. <p>* the Vesting of options is subject to the CEO remaining with the Company</p>
Termination and Notice:	This Agreement may be terminated by either the Company or the Executive, at any time by giving the other party hereto a notice period of 6 months



APPENDIX

Mr Sharon Malka – Biography

Sharon Malka, 51, is a seasoned executive with extensive experience of providing strategic, financial and operational leadership in the public and private sectors.

Malka is a results-driven leader with strong track record of execution, driving growth in high-paced innovative organizations.

Before joining Dotz, Malka served as Chief Executive Officer for MediWound Ltd, a Nasdaq-listed biopharmaceutical company, where he delivered executive leadership, identified and exploited new opportunities and secured hundreds of million through private and public equity offerings and strategic transactions. Prior to his appointment as CEO, he served as Chief Financial and Operations Officer, where he established the company's global commercialization strategy and certified pharmaceutical manufacturing capacity.

Malka was a partner at Variance Economic Consulting Ltd., a multi-disciplinary consulting boutique, specializing in financial services for international and local Hi-Tech clients.

Malka also served as a Senior Manager at PricewaterhouseCoopers Corporate Finance, where he gained extensive experience in company valuations, joint ventures and financial instruments for investments, M&A, and IPOs.

Mr. Malka is a certified CPA and holds a B.Sc. in Business Administration from the Business Management College in Israel and an M.B.A. from Bar Ilan University, Israel.

Malka serves as an active member of the board and a member of strategic advisory board for several global public healthcare companies.